Publication | Closed Access

Oral administration of MA-2029, a novel selective and competitive motilin receptor antagonist, inhibits motilin-induced intestinal contractions and visceral pain in rabbits

Motilin-induced Intestinal ContractionsVisceral PainGastrointestinal PharmacologyMedicinePhysiologyMechanism Of ActionOral AdministrationExperimental PharmacologyPharmacotherapyPharmacology